Department of Otorhinolaryngology, Isala Clinics, Zwolle, the Netherlands.
Department of Innovation and Science, Isala Clinics, Zwolle, the Netherlands.
Auris Nasus Larynx. 2020 Aug;47(4):609-615. doi: 10.1016/j.anl.2020.02.002. Epub 2020 Feb 26.
To evaluate the patient-reported reflux symptom index (RSI) and the doctors-reported Reflux finding score (RFS) as potential predictors for proton pump inhibitor (PPI) response in patients with suspected lower pharyngeal reflux, presenting with globus pharyngeus as their primary complaint.
The research project was performed at the ENT department of Isala hospital Zwolle, the Netherlands. A before and after design was used for this single institution prospective exploratory study. 101 participants with globus pharyngeus symptoms as a primary complaint were included. All participants were assessed by an otorhinolaryngologist at enrollment and after eight weeks of esomeprazole use. Fiberoptic laryngoscopy was performed to document the RFS, and RSI questionnaires were self-administered by the participants. Our main outcome measurement was the patient- reported therapeutic response evaluation, that differentiated three categories: responders, partial responders and non-responders. For evaluation of the assessment tools, RFS > 7 and RSI > 13 were considered deviant.
Among the 101 participants, 43 (42.6%) were responders, 28 (27.7%) partial responders and 30 (29.7%) non-responders. Both baseline RSI > 13 and RFS > 7 were statistically significant associated with treatment response. Also, combined into RSI/RFS baseline categories, a significant overall association between baseline scores and patient-reported treatment response was found. Patients reported success rates for deviant RSI and RFS baseline scores were 76.6% and 96%, respectively. 95.5% of patients with both deviant RSI and RFS baseline scores, reported (partial) treatment response.
Both together, as well individually, pre-treatment RSI and RFS ratings can help predict treatment response of empirical PPI treatment in patients experiencing globus pharyngeus symptoms.
评估患者报告的反流症状指数(RSI)和医生报告的反流发现评分(RFS),作为疑似下咽部反流患者质子泵抑制剂(PPI)反应的潜在预测指标,这些患者以咽部异物感为主要主诉。
该研究在荷兰兹沃勒的伊萨拉医院耳鼻喉科进行。这是一项单机构前瞻性探索性研究,采用前后设计。共纳入 101 例以咽部异物感为主要主诉的患者。所有患者在入组时和使用埃索美拉唑 8 周后均由耳鼻喉科医生进行评估。纤维喉镜检查记录 RFS,患者自行填写 RSI 问卷。我们的主要观察指标是患者报告的治疗反应评估,分为三个类别:应答者、部分应答者和无应答者。为评估评估工具,RSI>13 和 RFS>7 被认为是异常的。
在 101 名参与者中,43 名(42.6%)为应答者,28 名(27.7%)为部分应答者,30 名(29.7%)为无应答者。RSI 基线>13 和 RFS 基线>7 均与治疗反应显著相关。此外,RSI/RFS 基线评分联合分类,发现基线评分与患者报告的治疗反应之间存在显著的总体相关性。RSI 和 RFS 基线评分异常患者的报告成功率分别为 76.6%和 96%。95.5%的 RSI 和 RFS 基线评分均异常的患者报告(部分)治疗反应。
治疗前 RSI 和 RFS 评分无论是单独使用还是联合使用,都可以帮助预测接受经验性 PPI 治疗的咽部异物感患者的治疗反应。